On January 30, 2024 Breakpoint therapeutics reported that its Managing Directors Daniel Speidel and Jon Hollick will attend the DDR Inhibitors Summit 2024 in Boston (30 January- 1 February 2024) (Press release, Breakpoint Therapeutics, JAN 30, 2024, View Source [SID1234639705]). At this international meeting, experts from industry and academia gather to share and discuss updates in the development of novel therapeutics targeting the DNA Damage response in cancer cells.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Daniel Speidel will chair the conference and also moderate a panel entitled "What Makes the Perfect Next-Generation DDR Inhibitor Target?". In addition, Jon Hollick will present a poster highlighting new data from Breakpoint’s PolQ programme.